Neurology
-
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
This article has 6 authors:Reviewed by ScreenIT
-
Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function
This article has 20 authors:Reviewed by ScreenIT
-
The association between SARS-CoV-2 infection and neuronal damage: A population-based nested case-control study
This article has 3 authors:Reviewed by ScreenIT
-
Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia
This article has 14 authors:Reviewed by ScreenIT
-
COVID-19 Impact on Stroke Admissions during France’s First Epidemic Peak: An Exhaustive, Nationwide, Observational Study
This article has 8 authors:Reviewed by ScreenIT
-
COVID ‐19 Vaccine Response in People with Multiple Sclerosis
This article has 29 authors:Reviewed by ScreenIT
-
Rapid vigilance and episodic memory decrements in COVID-19 survivors
This article has 7 authors:Reviewed by ScreenIT
-
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
This article has 28 authors:Reviewed by ScreenIT
-
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets in Clinical Practice
This article has 11 authors:Reviewed by ScreenIT
-
SARS-CoV-2 is associated with changes in brain structure in UK Biobank
This article has 20 authors: